Download Pathfinder 2D and 3D Cell Proliferation Assays

RESEARCH SERVICES
Pathfinder 2D and 3D
Cell Proliferation Assays
Aid patient stratification, reveal resistance
mechanisms and support drug re-positioning
Reveal the effect of specific mutations on drug sensitivity by profiling your
compounds in Horizon’s X-MAN® isogenic cell line panels. Multiple cellular
backgrounds are available in our 2D and 3D cell proliferation assay service.
Pathfinder 2D: Analyze compound efficacy across a variety of genetic backgrounds.
Pathfinder 3D: Study phenotypes present in 3D environment that may not be detected in 2D.
t + 44 (0)1223 655 580 (UK) or +1 (855) 772-4252 (USA)
f + 44 (0)1223 655581
[email protected]
w www.horizondiscovery.com
Horizon Discovery, 7100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL, United Kingdom
Horizon Discovery offers profiling of your compounds in validated 2D and 3D isogenic cell line panels containing
mutations in specific cancer genes including EGFR, BRAF, KRAS, PI3KCA, PTEN and TP53.
Analyze how specific cancer genes and mutations affect drug response. Leverage 3D culture to re-capitulate
cell-cell and cell-matrix interactions and tumor microenvironment to study pathways, mutations and drugs that
produce a particular phenotype in 3D environment that maybe not be detected in 2D.
Pathfinder 2D
•
•
•
•
•
•
•
•
•
•
120
Choose cell lines from 5 standard X-MAN® isogenic cell
line panels*
KRAS panel
RAS-RAF-MEK panel
PI3K panel
Colon cancer panel
DNA damage panel
Optimized growth and assay conditions
10 point dose response curve
72 h treatment time (144 h for DNA damage panel)
Viability readout
Deliverables: Dose response curves and IC50 values
*Custom isogenic cell line panels are also available.
Viability (% of Control)
•
100
80
60
40
20
0
•
100
*Ask us which cell lines are included in Pathfinder 3D.
Custom panels are also available.
Viability (% of Control)
120
•
•
•
•
•
0 -9
-8
-7
-6
Log [g/ml] Erbitux®
-5
Figure 1. Response to Erbitux® in parental
and KRAS mutant SW48 colon cancer cells
Pathfinder 3D
Choose cell lines from selected X-MAN® isogenic cell lines
and 45 standard cancer cell lines*
Soft agar assay with optimized growth and assay conditions
10 point dose response curve
7-14 days treatment time
Viability readout
Deliverables: Dose response curves and IC50 values
Parental
KRAS G13D
KRAS G12C
3D
2D
80
60
40
20
0
0
-9
-8
-7
-6
Log [M] MEK inhibitor
-5
Figure 2. Response to MEK inhibitor in 2D vs.
3D in DLD-1 colon cancer cells
© Pathfinder 2D and 3D Cell Proliferation Assays 2015 v-02
t + 44 (0)1223 655 580 (UK) or +1 (855) 772-4252 (USA)
f + 44 (0)1223 655 581
[email protected]
w www.horizondiscovery.com
Horizon Discovery, 7100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL, United Kingdom